From July 10th to 11th, the multidisciplinary Curious2024 – Future Insight™️ Conference is bringing together some of the world’s brightest scientists, including several Nobel laureates, and the most accomplished innovators to present their work and explore the future of science and technology, solving the challenges of today and enabling the dreams of a better tomorrow.
Klineo raises €2m to speed up access to cancer trials
Latest NewsParis-based Klineo SAS has raised €2M to speed up access to clinical trials for oncology patients using an AI platform.
`
Locate Bio Ltd raises £9.2m venture capital
Latest NewsUniversity Nottingham spin out Locate Bio Ltd has added £9.2m venture financing led by Mercia Ventures and Business Growth Fund to its £16.2m raised before.
Electrochaea sells biomethane reactor to Again A/S
Latest NewsArchaeal Power-to-biomethan producer Electrochaea GmbH has sold a BioCat bioreactor to the Danish CCU specialist Again A/S.
Flindr Therapeutics BV secures €20m Series A financing
Latest NewsOss-based oncology company Flindr Therapeutics BV has secured €20m to advance it first-in-class RNF31 inhibitors, which destabilises E3 ubiquitin ligase.
Nordic Bioproducts Group opens its first production facility
Latest NewsFinnish Nordic Bioproducts Group has opened a production facility to produce advanced cellulosic materials wit the start-up’s AaltoCell technology
Curious2024 – Future Insight Conference
Sponsored PublicationsFrom July 10th to 11th, the multidisciplinary Curious2024 – Future Insight™️ Conference is bringing together some of the world’s brightest scientists, including several Nobel laureates, and the most accomplished innovators to present their work and explore the future of science and technology, solving the challenges of today and enabling the dreams of a better tomorrow.
New Chief Business Officer for Amarna Therapeutics
AppointmentsLeiden-based Amarna Therapeutics welcomed Aurelia Caparrós as its new Chief Business Officer (CBO) in April.
Swiss Biotech Report reporting record turnover
Latest NewsThe Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn. Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and 2022 (CHF1.3bn).
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
Latest NewsIpsen SA and RNA splicing modifier specialist Skyhawk Therapeutics Inc have entered a US$1.8bn licencing option deal in rare neurological disorders.
Seabelife SAS to develop next-gen dry AMD drug
Latest NewsFrench drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.